MINI FUTURE LONG - ELI LILLY & CO | Market Closed - Börse Stuttgart 15:51:30 2024-07-11 EDT | ||
| 62.31 EUR | -1.05% |
|
| Current month | +2.35% | ||
| 1 month | +5.32% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-07-11 | 62.31 | -1.05% |
| 24-07-10 | 62.97 | +0.64% |
| 24-07-09 | 62.57 | +2.93% |
| 24-07-08 | 60.79 | +2.69% |
| 24-07-05 | 59.2 | -0.59% |
Delayed Quote Börse Stuttgart
Last update July 11, 2024 at 03:51 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | Morgan Stanley |
| WKN | MD280U |
| ISIN | DE000MD280U8 |
| Date issued | 2022-03-01 |
| Strike | 258.2 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.56 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 63.09 € |
|---|---|
| Lowest since issue | 2.18 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
934.1
USD
Average target price
887.2
USD
Spread / Average Target
-5.03%
- Stock Market
- Certificates
- Certificat
